{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:20:20Z","timestamp":1775866820326,"version":"3.50.1"},"reference-count":15,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2005,10,1]],"date-time":"2005-10-01T00:00:00Z","timestamp":1128124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,10,1]],"date-time":"2005-10-01T00:00:00Z","timestamp":1128124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2005,10,1]],"date-time":"2005-10-01T00:00:00Z","timestamp":1128124800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2005,10,1]],"date-time":"2005-10-01T00:00:00Z","timestamp":1128124800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2005,10,1]],"date-time":"2005-10-01T00:00:00Z","timestamp":1128124800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2005,10,1]],"date-time":"2005-10-01T00:00:00Z","timestamp":1128124800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2005,10,1]],"date-time":"2005-10-01T00:00:00Z","timestamp":1128124800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2005,10]]},"DOI":"10.1016\/j.urology.2005.04.062","type":"journal-article","created":{"date-parts":[[2005,10,18]],"date-time":"2005-10-18T07:20:50Z","timestamp":1129620050000},"page":"726-731","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":86,"title":["Intravesical gemcitabine therapy for superficial transitional cell carcinoma: Results of a Phase II prospective multicenter study"],"prefix":"10.1016","volume":"66","author":[{"given":"Riccardo","family":"Bartoletti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tommaso","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro","family":"Gacci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianluca","family":"Giubilei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizio","family":"Viggiani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio","family":"Santelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Repetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Nerozzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Ghezzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Sisani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2005.04.062_bib1","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/S0022-5347(17)37316-0","article-title":"Incidence and treatment of complication of bacillus Calmette-Gu\u00e9rin intravesical therapy in superficial bladder cancer","volume":"147","author":"Lamm","year":"1992","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2005.04.062_bib2","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0094-0143(21)00419-5","article-title":"Complications of intravesical chemotherapy","volume":"19","author":"Thrasher","year":"1992","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.urology.2005.04.062_bib3","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMoa011954","article-title":"Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer","volume":"346","author":"Schiller","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urology.2005.04.062_bib4","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer","volume":"15","author":"Burris","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2005.04.062_bib5","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/j.1349-7006.2001.tb01130.x","article-title":"The antitumor mechanism of 1-(2-deoxy-2-fluoro-4-thio-beta-d-arabinofuranosyl)-cytosine","volume":"92","author":"Miura","year":"2001","journal-title":"Jpn J Cancer Res"},{"key":"10.1016\/j.urology.2005.04.062_bib6","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00280-003-0661-5","article-title":"The role of DNA synthesis inhibition in the cytotoxicity of 2\u2032,2\u2032-difluoro-2\u2032-deoxycytidine","volume":"52","author":"Ostruszka","year":"2003","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.urology.2005.04.062_bib7","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.1997.15.12.3441","article-title":"Gemcitabine","volume":"15","author":"Moore","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2005.04.062_bib8","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.1200\/JCO.1997.15.11.3394","article-title":"Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer","volume":"15","author":"Stadler","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2005.04.062_bib9","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0959-8049(98)00030-6","article-title":"A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum","volume":"34","author":"Lorusso","year":"1998","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.urology.2005.04.062_bib10","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1200\/JCO.2003.09.028","article-title":"Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder","volume":"21","author":"Laufer","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2005.04.062_bib11","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.eururo.2003.09.014","article-title":"Intravesical gemcitabine","volume":"45","author":"Witjes","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2005.04.062_bib12","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/j.1464-410X.2003.04656.x","article-title":"Intravesical administration of gemcitabine in superficial bladder cancer","volume":"93","author":"De Beradinis","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2005.04.062_bib13","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2002.02.066","article-title":"Phase I trial of intravesical gemcitabine in bacillus Calmette-Gu\u00e9rin-refractory transitional-cell carcinoma of the bladder","volume":"20","author":"Dalbagni","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2005.04.062_bib14","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0302-2838(01)00026-4","article-title":"Guidelines on bladder cancer","volume":"41","author":"Oosterlinck","year":"2002","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2005.04.062_bib15","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1097\/01.ju.0000062605.92268.c6","article-title":"Defining bacillus Calmette-Gu\u00e9rin refractory superficial bladder tumors","volume":"169","author":"Herr","year":"2003","journal-title":"J Urol"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429505006321?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429505006321?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T01:41:37Z","timestamp":1758764497000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429505006321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,10]]}},"alternative-id":["S0090429505006321"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2005.04.062","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2005,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intravesical gemcitabine therapy for superficial transitional cell carcinoma: Results of a Phase II prospective multicenter study","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2005.04.062","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}